A headline price is a bet on a probability

Two items in the same week frame the same idea from opposite ends. Astellas agreed to partner with Audax on a preclinical IL-12 antibody-cytokine fusion, with up to about $285 million in upfront and option payments and up to roughly $1.05 billion in milestones, a total of up to about $1.34 billion before royalties, for a program not expected to reach Phase 1 until 2027. In the same week, Novartis recorded a partial impairment of about $1.9 billion against del-desiran after the Phase 3 HARBOR trial missed in myotonic dystrophy, an asset it had acquired through a roughly $12 billion purchase about a year earlier.

A headline price is a bet on a probability. Astellas is paying real money today for the chance that an early program works. Novartis paid a large sum for an asset whose probability later fell, and the accounting adjustment is that bet coming due. Neither company is wrong to play the odds; pricing risk is the business. What the pair shows is that the number attached to an asset is only ever an estimate of how likely it is to succeed.

That is why de-risking is the lever that matters. Every verified result narrows the gap between what a buyer hopes and what a buyer knows, and that is the gap that sets the price. For the owners we represent, the goal is to close as much of that gap as possible before going to market, so the buyer is pricing evidence rather than hope.

Nothing here is investment advice, and this note is not an endorsement of any transaction described. Figures are as publicly reported.

Work with Modulus

Filling a pipeline gap?

Talk to us →

Have a program worth de-risking?

See how we work with inventors →